Vaccine‐induced immune thrombotic thrombocytopenia (VITT) – a novel clinico‐pathological entity with heterogeneous clinical presentations-Reference-Cited by-同舟云学术

Vaccine‐induced immune thrombotic thrombocytopenia (VITT) – a novel clinico‐pathological entity with heterogeneous clinical presentations

Published:2021-06-22 Issue:1 Volume:195 Page:76-84
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Lavin Michelle¹²^ORCID,Elder Patrick T.³,O’Keeffe Denis⁴,Enright Helen⁵,Ryan Eileen⁵,Kelly Anna⁶,El Hassadi Ezzat⁷,McNicholl Feargal P.³,Benson Gary⁸,Le Giao N.¹,Byrne Mary¹,Ryan Kevin¹,O’Connell Niamh M.¹,O’Donnell James S.¹²

Affiliation:

1. National Coagulation Centre St. James’s Hospital DublinIreland

2. Irish Centre for Vascular Biology School of Pharmacy and Biomedical Sciences RCSI Dublin Ireland

3. North West Cancer Centre Altnagelvin Area Hospital Derry Northern Ireland

4. Department of Haematology University Hospital Limerick LimerickIreland

5. Department of Haematology Tallaght University Hospital DublinIreland

6. Department of Medicine Wexford General Hospital WexfordIreland

7. Department of Haematology University Hospital Waterford Waterford Ireland

8. Haemophilia and Thrombosis Centre Belfast City Hospital Belfast Northern Ireland UK

Funder

3M Foundation

Health Research Board

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.17613

Reference12 articles.

1. EMA & AstraZeneca.VAXZEVRIA/COVID‐19 Vaccine AstraZeneca : link between the vaccine and the occurrence of thrombosis in combination with thrombocytopenia[cited 2021 April 21]. Available at:https://www.ema.europa.eu/en/documents/dhpc/direct‐healthcare‐professional‐communication‐dhpc‐vaxzevria‐previously‐covid‐19‐vaccine‐astrazeneca_en‐0.pdf.

2. Centers for Disease Control and Prevention.Joint CDC and FDA Statement on Johnson & Johnson COVID‐19 Vaccine[cited 2021 April 21]. Available at:https://www.cdc.gov/media/releases/2021/s0413‐JJ‐vaccine.html.

3. Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination

4. Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination

5. Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Changes in haemostasis and inflammatory markers after mRNA BNT162b2 and vector Ad26.CoV2.S SARS-CoV-2 vaccination;Thrombosis Research;2023-08

2. Re-evaluation of the risk of venous thromboembolism after COVID-19 vaccination using haematological criteria;Vaccine;2023-08

3. Thrombosis with thrombocytopenia syndrome: A database review of clinical trial and post-marketing experience with Ad26.COV2.S;Vaccine;2023-08

4. Management of coronavirus disease 2019 vaccine-induced cutaneous complications: A comprehensive literature review;Journal of Family and Community Medicine;2023

5. D-dimer testing: A narrative review;Advances in Clinical Chemistry;2023